ReviewSignal transduction and targeted therapy2024
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies.
Review in Signal transduction and targeted therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 581 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
581 citing papers in PubMed, 598 citations in OpenAlex.
- PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Trial
- An endoplasmic reticulum-enriched nanogel couples ferroptotic tumor damage with macrophage reprogramming for triple-negative breast cancer immunotherapy.Bioactive materials · 2027Article
- Prognostic risk modeling based on integrated multi-omics analysis identifies CRY2 as a key regulator in tumor immunity and patient survival in colorectal cancer.Annals of medicine · 2026Article
- Engineered nanodendritic sonosensitizers empower sonodynamic-elicited ferroptosis and PANoptosis against platinum-resistant breast cancer.Materials today. Bio · 2026Article
- Research progress of ferroptosis in cervical cancer treatment.Annals of medicine · 2026Review
- FTO-mediated mRNA biology · 2026Article
- PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.Journal of enzyme inhibition and medicinal chemistry · 2026Review
- Advancing the understanding of the immune escape in lung cancer immunotherapy: Global trends, collaborations, and future directions.Human vaccines & immunotherapeutics · 2026Article
- Research progress of ferroptosis in gynecological diseases.Annals of medicine · 2026Review
- Targeting host ferroptosis in cancer cachexia: Tumor-immune triggers, tissue wasting, and the therapeutic paradox.iScience · 2026Review
- Single-cell transcriptomics identifies PRDX1 and GPX4 as potential ferroptosis regulators and tumor microenvironment--related molecules in hepatocellular carcinoma.Oncology letters · 2026Article
- KLF2 as a prognostic and potential therapeutic target associated with ferroptosis in serous ovarian cancer: An integrative bioinformatics and clinical validation study.Oncology letters · 2026Article
- Exploring Ferroptosis: A Key Mechanism in Respiratory System Diseases and its Therapeutic Potential.Applied biochemistry and biotechnology · 2026Review
- Reprogramming of cell death in gastric cancer: From molecular mechanisms to therapeutic potential (Review).International journal of molecular medicine · 2026Review
- Ferroptosis in health and disease.Molecular biomedicine · 2026Review
- Ferroptosis in cancer: molecular mechanisms, tumour microenvironment, therapeutic resistance, and clinical translation.Journal of the Egyptian National Cancer Institute · 2026Review
- Mitofusin 2 orchestrates mitochondrial metabolic homeostasis and suppresses cutaneous squamous cell carcinoma by stabilizing ER-mitochondria contacts.Journal of bioenergetics and biomembranes · 2026Article
- Stress-induced vtRNA1-1 modulates redox homeostasis and ferroptosis susceptibility in hepatocellular carcinoma cells.Redox biology · 2026Article
- A Dual-Delivery System Designed to Overcome EV-Mediated Ferroptosis Resistance for Efficient Solid Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
521 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
Abstract
Ferroptosis is a non-apoptotic form of regulated cell death characterized by the lethal accumulation of iron-dependent membrane-localized lipid peroxides. It acts as an innate tumor suppressor mechanism and participates in the biological processes of tumors. Intriguingly, mesenchymal and dedifferentiated cancer cells, which are usually resistant to apoptosis and traditional therapies, are exquisitely vulnerable to ferroptosis, further underscoring its potential as a treatment approach for cancers, especially for refractory cancers. However, the impact of ferroptosis on cancer extends beyond its direct cytotoxic effect on tumor cells. Ferroptosis induction not only inhibits cancer but also promotes cancer development due to its potential negative impact on anticancer immunity. Thus, a comprehensive understanding of the role of ferroptosis in cancer is crucial for the successful translation of ferroptosis therapy from the laboratory to clinical applications. In this review, we provide an overview of the recent advancements in understanding ferroptosis in cancer, covering molecular mechanisms, biological functions, regulatory pathways, and interactions with the tumor microenvironment. We also summarize the potential applications of ferroptosis induction in immunotherapy, radiotherapy, and systemic therapy, as well as ferroptosis inhibition for cancer treatment in various conditions. We finally discuss ferroptosis markers, the current challenges and future directions of ferroptosis in the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.